EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Acquired drivers of C3 glomerulopathy

Seth J Welsh iD, Yuzhou Zhang, Richard J H Smith

Clinical Kidney Journal · 04.03.2025 · 18 (3)

DOI: 10.1093/ckj/sfaf022 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Kidney Journal, online erschienen am 27.01.2025. Verfasst von Seth J Welsh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Molecular Otolaryngology and Renal Research Laboratories, Carver College of Medicine, University of Iowa, Iowa City,…. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

C3 glomerulopathy (C3G) is a group of heterogeneous ultrarare kidney diseases characterized by dysregulated activation of the complement alternative pathway (AP) leading to excessive C3 cleavage. Diagnosis relies on kidney biopsy showing predominant C3 deposition in the glomerular basement membrane, with electron microscopy differentiating between dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). The main drivers of AP dysregulation in C3G are acquired rather than genetic and consist primarily of autoantibodies called nephritic factors (C3Nefs, C4Nefs and C5Nefs) that bind to and stabilize complement convertases, causing complement overactivation. Current therapies are largely supportive, and existing complement-targeting treatments, such as eculizumab, demonstrate limited efficacy. Challenges in studying C3G include variability in autoantibody detection and a lack of standardized assays, which complicates clinical interpretation. Comprehensive assessment involving autoantibody panels, complement biomarkers, functional assays and genetic testing provides a more complete understanding of disease dynamics; however, key knowledge gaps remain regarding Nef origins, mechanisms and their pathogenic role. In this review we discuss acquired drivers of C3G with an emphasis on C3Nefs and C5Nefs and suggest areas of interest that might benefit from future research.

Schlagwörter

Stichwörter der Autor:innen

C3 convertaseC3 glomerulopathyautoimmune diseasecomplementnephritic factor

Autor:innen und Institutionen

  • Department of Internal Medicine, Molecular Otolaryngology and Renal Research Laboratories, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.

ORCID-Profile: Seth J Welsh

Förderung

  • NIDDK NIH HHS
  • National Institutes of Health

Zitieren

APA

Welsh, S. J., Zhang, Y., & Smith, R. J. H. (2025). Acquired drivers of C3 glomerulopathy. Clinical Kidney Journal, 18(3). https://doi.org/10.1093/ckj/sfaf022

Vancouver

Welsh SJ, Zhang Y, Smith RJH. Acquired drivers of C3 glomerulopathy. Clinical Kidney Journal. 2025;18(3). doi:10.1093/ckj/sfaf022

BibTeX
@article{Welsh2025,
  author = {Welsh, Seth J and Zhang, Yuzhou and Smith, Richard J H},
  title = {Acquired drivers of C3 glomerulopathy},
  journal = {Clinical Kidney Journal},
  year = {2025},
  volume = {18},
  number = {3},
  doi = {10.1093/ckj/sfaf022}
}
Kostenlos starten →